I completely understand the frustration. In most situations, especially ones this high-profile and prolonged, some kind of shareholder update would feel warranted. But in this case, the silence is not only explainable, it’s likely necessary.
Here’s why.
We know from the MHRA’s published protocol that after internal approval is granted, there’s a structured post-decision period where the agency collaborates with the company to finalize all public-facing documentation. This includes the Summary of Product Characteristics (SmPC), the Public Assessment Report (PAR), and any accompanying press release. During this time, the company reviews the MHRA’s draft materials, ensures no confidential information is disclosed, and confirms alignment on the final language. Only once those documents are approved and locked is the announcement made public.
Now, if DCVax-L is classified as a New Active Substance (NAS) which is highly likely given its novel, personalized mechanism, MHRA is required to issue a press release within 7 days and a PAR within 30 days of authorisation. But, and this is crucial, those clocks start at internal approval, not public disclosure. And the labeling process can be slower and more sensitive if the therapy is being positioned for a tissue-agnostic indication or broader platform use. That kind of scope would require extra scrutiny on safety language, indication phrasing, dosing language across tumor types, and manufacturing traceability under SI 87. That’s not something NWBO can or should pre-empt in a press release or shareholder update.
In that regulatory window, any communication from the company has to match what MHRA is about to publish. If NWBO were to issue a vague or forward-leaning statement, even a soft acknowledgment, it could contradict the precise language MHRA is finalizing. That misalignment could lead to regulatory pushback, delay the PAR publication, or even trigger reputational concerns. In short, the margin for error is razor thin.
And that’s why the silence makes sense.
Think of it like this: a student has completed all their classes, passed their final exams, and already received informal confirmation from their advisor that they’ve graduated. But the university still has to finalize the official transcript. That means checking the credit totals, confirming GPA calculations, ensuring that every course title is accurate, and that no sensitive notes are accidentally left on the final record.
Now imagine the student announces their graduation on social media before the transcript is finalized, and it turns out there’s a typo or a pending grade correction. Suddenly, they’ve created confusion and undermined the credibility of what should have been a smooth and celebratory moment.
That’s exactly where NWBO likely is. They’ve passed the finish line behind the scenes, but they’re still aligning with the MHRA on final documents. And because this isn’t just any therapy, it’s a cell-based, patient-specific, potentially tissue-agnostic immunotherapy, the language in the SmPC and PAR has to be airtight. Any misstep in public communication, even if well-intended, could risk regulatory friction or delay.
✅ Bottom Line:
So yes, while it’s natural to want reassurance, the very lack of a statement is likely evidence of how close we are. This silence doesn’t come from neglect. It comes from precision. From discipline. And from the reality that, right now, it’s not about messaging, it’s about execution. Structurally, we are in the final window. The company is aligning the last words. The document is being signed. The diploma is being sealed.
And when it drops, it will be official, complete, and irreversible.
AI
Market Data 
Markets 
